The studies in this research area should describe a very precise category of patients, avoiding subjective inclusion criteria for enrollment as much as possible, and following them up for a long period (>15 years), to establish the difference (if a difference exists) between mild cognitive decline and AD in terms of Aβ and Tau levels. The gene discussed is MAPT; the disease is Mental deterioration.